Citations

Clear

409 citation(s) found for "Rivera, A".

Clinical significance of anti‐M in pregnancy and self‐reported ancestry: The BEST collaborative study
Lu, Wen , Ziman, Alyssa , Yan, M. T. S., Virk, Mrigender , Stephens, Laura D. , Radwi, Ghazala, Morrison, Douglas, Marrero‐Rivera, Gisela , Ly, Judy , Ikeda, Kazuhiko, Hands, Katie , Malti, Salwa El, Eichbaum, Quentin , Covello, Thomas, Chang, Shelley, Brancamp, Rachel , Badawi, Maha, AlMozain, Nour, Shan, Hua , Collaborative, The Biomedical Excellence for Safer Transfusion, AlMozain, Nour , Yin, Charles , Yan, Matthew T S , Stephens, Laura , Marrero-Rivera, Gisela , Hasan, Rida A , Clarke, Gwen , Bakhtary, Sara , Badawi, Maha , Ziman, Alyssa , Lu, Wen , Almozain, Nour , Raval, Jay S. , Radwi, Ghazala , Ly, Jane, Juskewitch, Justin E. , Ikeda, Kazuhiko, Hasan, Rida A. , Duncan, Jennifer, Bakhtary, Sara , Au, Nicholas H. C.

Mayo Clinic

Transfusion | April 6, 2026 | Volume: 66 | Issue: 6 | Pages: 1086-1098

10.1111/trf.70210 | PMID 41937612 Get It

Abstract Background Anti‐M antibodies were described as rarely eliciting hemolytic disease of the fetus and newborn (HDFN) in pregnancy. More recent literature, primarily from Asia, reports severe HDFN attributed to maternal anti‐M. The objective of this study is to determine if there is a difference in the frequency and/or severity of anti‐M HDFN among subjects who self‐report as Asian compared to non‐Asian. Methods Retrospective data were collected from 18 sites. Fetuses/neonates affected by HDFN were categorized as unaffected, mild, moderate, or severe based on clinical management and outcomes. Results Anti‐M was identified in 557 obstetric patients. Among 332 neonates with complete data for analysis, anti‐M was detected in isolation during the pregnancies of 210 (63.3%) neonates; 198 (94.3%) were unaffected by HDFN. The overall frequency of HDFN was 6.5% (2/31) in Asian patients and 5.6% (10/179) in non‐Asian patients. The frequency of severe HDFN was 6.5% (2/31) among Asian patients and 0.6% (1/179) among non‐Asian patients. Among non‐Asian patients, eight (4.5%) were mild and one (0.6%) was moderate. Of 63 pregnancies with anti‐M and ABO incompatibility, 6 (9.5%) were associated with mild HDFN and 57 (90.5%) were unaffected. Of 49 pregnancies with anti‐M and non‐ABO antibody(s), 6 (12.2%) were associated with mild HDFN and 43 (87.8%) were unaffected. One case (10.0%) of HDFN (mild) occurred in the presence of anti‐M, additional antibody(s), and ABO incompatibility. Conclusion In this study, severe anti‐M HDFN was rare in non‐Asian subjects. There is a signal that Asian patients are at greater risk for severe anti‐M HDFN.
Abstract 6137: Multi-omicsinpostoperative lymphatic exudate in HPV-negative head and neck cancer
Costliow, Zachary A., Lazare, Seka , Gu, Zhuosheng, Harmon, Adam, Rivera, Megan, Chaudhuri, Aadel A. , Zevallos, Jose P., Ubellacker, Jessalyn Marie, Winckler, Wendy , Gu, Zhuosheng , Pacula, Maciej , Rivera, Megan , Zevallos, Jose P. , Ubellacker, Jessalyn M.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6137-6137

10.1158/1538-7445.am2026-6137 Get It

Abstract Our team has demonstrated that lymphatic exudate collected via surgical drains (“lymph”) is a proximal biofluid rich in ctDNA and prognostic of recurrence in HPV-independent Head and Neck Cancer (HPV- HNSCC). Other analytes such as proteins, metabolites, and cells are also abundant in lymph. To understand the liquid tumor microenvironment (TME) immediately after tumor resection, we characterized lymph at 24 hrs in HNSCC. We performed a multi-omic survey, demonstrating that lymph is distinct from plasma and represents a largely unexplored source of biomarkers relevant to immune modulation and metastasis.Metabolomics and proteomics were run on lymph supernatant and plasma. Proteomic screening was performed via Olink and normalized to internal standards for quantitative analysis. Metabolomic samples were assayed via LC-MS and normalized. 16s libraries were sequenced utilizing Illumina and analyzed in QIIME. 16s sequencing on 6 patients indicated an array of bacterial genera present in post-surgical lymph with consistency across patients. The distribution consisted primarily of microbes native to the oral cavity, suggesting post-surgical lymph may reflect the native microbiome prior to surgery. Pathogenic blooms were observed in a subset of patients. Ongoing analysis will correlate microbiome data with both cancer and surgical outcomes.Metabolite profiling was performed on post-surgical lymph and matched plasma from 4 patients, including 3 who recurred within 1 year of surgery. The metabolite profile in lymph of all 4 patients was more diverse than plasma with higher metabolite abundance per mL. 13% of identified metabolites were >2-fold enriched in lymph. Lymph from recurred patients showed high levels of saturated and monounsaturated fatty acids, reported to be associated with metastasis. Post-surgical lymph has a unique and largely uncharted metabolome to mine for biomarkers associated with recurrence.Proteomes were compared between lymph and plasma from 44 HPV-HNSCC patients. This cohort consists of 25 recurred (REC) and 19 patients with no evidence of disease (NED) with >1 year of follow up. Lymph and plasma displayed highly non-overlapping protein repertoires. The mean absolute volcano score was 25.2, indicating a strong global difference between lymph and plasma. Lymph was significantly enriched in 91 proteins (p range 4.1e-47 to 0.037), many associated with inflammation. REC lymph was also enriched in inflammatory markers compared to NED, including IL-1a, TNF, and TSLP (p = 0.002, 0.015, 0.003, respectively), which have been implicated in cancer metastasis, invasion, and angiogenesis. Lymph hits were largely non-overlapping with plasma, indicating the opportunity for novel biomarker discovery in this fluid.Analysis of the microbiome, metabolome, and proteome of post-surgical lymph reveals a rich and differentiated tumor-adjacent biofluid to study biomarkers relevant to metastasis and the TME. Citation Format: Zachary Costliow, Seka Lazare, Zhuosheng Gu, Adam Harmon, Maciej Pacula, Megan Rivera, Aadel A. Chaudhuri, Jose P. Zevallos, Jessalyn Marie Ubellacker, Wendy Winckler. Multi-omicsinpostoperative lymphatic exudate in HPV-negative head and neck cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6137.
Show Me the “Mino:” In Vitro Efficacy of Minocycline on Clinical Gram-Negative Bacterial Isolates
Streck, Nicholas , Saleh, O. Abu, Crowley, Patrick D , Mira, Portia , Challener, Douglas W. , Abu Saleh, Omar , Crowley, Patrick D., Ranganath, Nischal , Rivera, Christina G. , AbuSaleh, Omar

Mayo Clinic

Microbial Drug Resistance | March 31, 2026 | Volume: 32 | Issue: 4 | Pages: 128-134

10.1177/10766294261424485 | PMID 41677880 Get It

Background: There are limited oral treatment options available for resistant Gram-negative bacterial (GNB) infections. Minocycline, a second-generation tetracycline antibiotic, offers good bioavailability and broad-spectrum coverage that may be an option for GNB infections. Methods: We conducted a retrospective review of minocycline susceptibility testing performed on GNB isolates at the Mayo Clinic reference lab between 2013 and 2022. Minocycline susceptibility was evaluated with a focus on difficult-to-treat organisms and relevant anatomic source. Organisms included resistant isolates of Escherichia coli and Klebsiella pneumoniae ; high-risk ampC-derepressors, including Citrobacter freundii, Enterobacter cloacae, and K. aerogenes; and clinically challenging non-Enterobacterales, Acinetobacter species, Achromobacter species, and Stenotrophomonas maltophilia . Results: Of 217,206 GNB isolates, 18,148 Enterobacterales (EB) and 8,190 non- Enterobacter isolates were tested for minocycline susceptibility. Of these, 80% of all EB and 92% of non-EB isolates were susceptible. Among E. coli isolates with ceftriaxone, ciprofloxacin, meropenem, or multidrug resistance, minocycline susceptibility was 78%, 76%, 70%, and 70.9%, respectively. Among the K. pneumoniae isolates with ceftriaxone, ciprofloxacin, meropenem, or multidrug resistance, minocycline susceptibility was 46%, 38%, 37%, and 39.3%, respectively. 85% of C. freundii , 81% of E. cloacae, and 85% of K. aerogenes isolates were susceptible to Minocycline. 83.5% of Achromobacter species isolates, 66% of Acinetobacter species isolates, and 99.1% of S. maltophilia isolates were susceptible. Conclusions: Our study reports the largest collection of minocycline susceptibility findings in GNB. Minocycline showed in vitro activity against many difficult-to-treat GNB isolates, including ceftriaxone- and multidrug-resistant E. coli and some K. pneumoniae isolates, common Amp-C-producing species, and non-fermenting GNB, including Stenotrophomonas , Acinetobacter , and Achromobacter .
3-Mercaptopyruvate sulfurtransferase regulates mitochondrial metabolism and epithelial differentiation in neonatal patient-derived airway cells
Ganguly, Abhrajit , Carter, Cynthia M., Negron, Aristides Rivera, Pierce, Paul T., Walters, Matthew S. , Prakash, Y. S., Tipple, Trent E. , Richardson, Arlan , Prakash, Y. S. , Walters, Matthew S , Prakash, Y S , Tipple, Trent E , Carter, Cynthia, Rogers, Lynette Kay

Mayo Clinic

American Journal of Physiology-Lung Cellular and Molecular Physiology | March 28, 2026 | Volume: 330 | Issue: 5 | Pages: L557-L566

10.1152/ajplung.00418.2025 | PMID 41902666 Get It

This study identifies 3-mercaptopyruvate sulfurtransferase (MPST) as a previously unrecognized regulator of neonatal airway epithelial development. In our neonatal patient-derived three-dimensional organotypic model, hyperoxia reduces MPST, and MPST loss alters mitochondrial metabolism and epithelial differentiation programs. These findings indicate that MPST deficiency contributes to mitochondrial dysfunction under hyperoxic conditions and highlight MPST-linked pathways as potential therapeutic targets to mitigate early-life airway injury and remodeling relevant to infants with bronchopulmonary dysplasia (BPD).
International real-world study on osilodrostat efficacy and safety in adrenal Cushing syndrome
Araujo-Castro, Marta, Bancos, I., Detomas, Mario, Reincke, Martin, Mahdi, Salehi, Lu, Haibo , Altieri, Barbara , Kroiss, Markus, Oettle, Matthias , Guerrero-Pérez, Fernando, Hanzu, Felicia A, García-Centeno, Rogelio , Gónzalez-Fernandez, Laura, Pasarón, María, Gimeno, Paola Gracia, Valero, Luis Candil , Luna, Ana Castro, García-Agulló, María Dolores Ollero, Araujo‐Castro, Marta , Salehi, Mahdi , Araujo-Castro, Marta , Bancos, Irina , Detomas, Mario , Reincke, Martin , Rivera Martínez, Wilfredo Antonio , Bancos, Irina , Reincke, Martín , Guerrero‐Pérez, Fernando , Hanzu, Felicia Alexandra , Fernández, Laura González , Fernández, María Pasarón, Luna, Ana Castro, Echarri, Ana

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 12, 2026 | Volume: 111 | Issue: 8 | Pages: 2180-2189

10.1210/clinem/dgag115 | PMID 41824768 Get It

Abstract Context Most of the patients included in the clinical trials and real-world studies with osilodrostat only include patients with adrenocorticotropic hormone dependent Cushing syndrome (CS), while data on the efficacy and safety of osilodrostat in patients with adrenal CS is scarce. Objective To assess the efficacy and safety of osilodrostat in adrenal CS. Methods International study of patients with adrenal CS: patients treated with osilodrostat at any time were enrolled in the safety evaluation and those treated for longer than 4 weeks, in the efficacy evaluation. Patients were classified as responders if they experienced a reduction in urinary free cortisol (UFC) >50% (complete responders when UFC levels were below the upper limit of normal [ULN] and partial responders if there was a reduction >50% but not normalization). Results Twenty-eight patients with adrenal CS were enrolled: 16 with adrenocortical carcinoma and 12 with benign disease. Osilodrostat was used in monotherapy in 22 patients and in combination with metyrapone in 6 cases. In those patients treated for longer than 4 weeks (n = 21), 66.7% were classified as responders (28.6% with complete response and 38.1% with partial response), and for those treated for longer than 12 weeks, the rate of response increased to 87.5% The use of osilodrostat as a nonfirst-line therapy (odds ratio 15.0, P = .010) was a predictor of response. Osilodrostat led to a significant decrease in systolic blood pressure and body weight (P < .05). Nine patients developed one or more adverse events and in 56% (n = 5) led to osilodrostat discontinuation. Conclusion Osilodrostat controls hypercortisolism in 66.7% of patients with adrenal CS treated for longer than 4 weeks and in 87.5% of cases treated for longer than 12 weeks, with a positive impact on blood pressure and body weight. Patients who received osilodrostat after other previous steroidogenesis inhibitors have a higher probability of response.
Hypertensive Disorders of Pregnancy: Factors Associated with Multiple Postpartum Blood Pressure Visits
Dyre, Lillian , Falde, Danielle L., Branda, Megan E. , Theiler, Regan N. , Tobah, Yvonne Butler , Rivera‐Chiauzzi, Enid Y. , Dyre, Lillian J , Butler Tobah, Yvonne S , Rivera-Chiauzzi, Enid Y , Branda, Megan , Theiler, Regan

Mayo Clinic

American Journal of Perinatology | March 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2809-6441 | PMID 41776841 Get It

Abstract Patients with hypertensive disorders of pregnancy (HDPs) are recommended to attend an early postpartum follow-up visit for blood pressure monitoring. Follow-up frequency for patients with HDPs can vary widely, with some patients requiring multiple office visits. We sought to determine factors associated with multiple postpartum blood pressure visits among patients with HDPs. We retrospectively identified patients with HDPs who delivered at our maternity center in 2019 and compared factors between patients who attended a single blood pressure follow-up appointment without requiring further clinical evaluation for hypertension and patients who required multiple postpartum clinical evaluations for persistent hypertension. Univariate logistic regression models were used to identify factors associated with increased odds of having multiple clinically indicated postpartum visits for blood pressure monitoring. We identified 328 patients with HDPs, of whom 260 (79.3%) attended an initial postpartum blood pressure follow-up appointment and were included in further analyses. Of the 260 patients, 70 (26.9%) had multiple blood pressure visits. Factors associated with multiple blood pressure visits included delivery between 34 and less than 37 weeks of gestation (odds ratio [OR], 3.62; 95% CI, 1.07–12.30), systolic blood pressure before discharge of 140 mm Hg or higher (OR, 5.02; 95% CI, 2.57–9.82), and discharge with blood pressure medication (OR, 3.42; 95% CI, 1.82–6.41). Patients with HDPs who deliver preterm, have persistent hypertension before discharge, or are discharged with antihypertensive medication require continued close postpartum observation and continuity of care.
Outcomes of nephrectomy in patients with pathologic complete response to immune checkpoint inhibitor therapy for renal cell carcinoma: A multicenter study.
Ghoreifi, Alireza, Sobhani, Sina , Lopez, Carlos Rivera, Helstrom, Emma, Deol, Ekamjit S. , KHENE, Zine-Eddine, Gill, Inderbir, Thompson, Robert Houston, Tachibana, Isamu Tachibana, Khanna, Abhinav, Lee, R. Jeffrey, Uzzo, R., Margulis, Vitaly, Singla, Nirmish, Djaladat, Hooman, Ghoreifi, Alireza , Ghoreifi, Alireza , Moghaddam, Farshad Sheybaee , Basin, Michael F. , Lopez, Carlos A. Rivera , Khene, Z. , Gill, Inderbir, Thompson, R. Houston, Tachibana, Isamu , Margulis, Vitaly, Djaladat, Hooman

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 454-454

10.1200/jco.2026.44.7_suppl.454 Get It

454 Background: Immune checkpoint inhibitor (ICI)-based combination therapy has become the standard of care for advanced renal cell carcinoma (RCC). A pathologic complete response (pCR) in the primary tumor may be observed in up to one-third of patients; however, data on the outcomes of these patients remain limited. This study aimed to evaluate the clinical outcomes of patients who achieved a pCR following ICI therapy. Methods: Patients with advanced RCC who underwent nephrectomy following ICI therapy were evaluated across five high-volume U.S. academic centers between 2015 and 2023. Clinical characteristics and outcomes were compared between those with and without a pCR in the primary tumor (ypT0N0/Nx). Multivariable logistic regression models were used to identify factors associated with pCR. Recurrence-free (RFS) and overall survival (OS) rates were estimated using the Kaplan-Meier (KM) method. Results: A total of 182 patients were included (Table 1). Among all patients, downstaging to ≤ypT1N0/Nx was observed in 45 patients (25%), of whom 21 (11%) achieved a pCR. In multivariable analysis, the presence of clinical thrombus was marginally associated with a lower likelihood of achieving pCR (odds ratio [95% CI]: 0.39 [0.15–1.00], p=0.06). During a median follow-up of 25 months, 70 patients (38%) experienced recurrence, including 4 (2%) in the pCR group. Median time to recurrence was 7.5 months. KM analysis demonstrated a higher estimated 5-year RFS in the pCR group compared to those with residual disease; however, the difference was not statistically significant (68% vs. 54%, p=0.2). In addition, OS rates were comparable between the two groups. Conclusions: In our cohort, 11% of patients who underwent nephrectomy following ICI therapy for advanced RCC showed pCR, which correlated with improved oncologic outcomes. Despite the lower recurrence rates observed in the pCR group, sustained long-term surveillance remains necessary due to the continued, albeit reduced, risk of disease recurrence. Clinical characteristics of patients who underwent post-ICI nephrectomy, stratified by their pathologic complete response (pCR). Variable pCR (n=21) No pCR (n=161) p-value Median (IQR) age, year 61 (56 – 70) 64 (56 – 71) 0.46 Gender (male), n (%) 15 (71) 118 (73) 0.8 Tumor advancement, n (%) Locally advanced Metastatic 2 (10)19 (90) 36 (22)125 (78) 0.26 Risk group (for metastatic), n (%) Favorable Intermediate Poor 3 (25)6 (50)3 (25) 38 (34)59 (54)13 (12) 0.42 ICI regimen, n (%) ICI monotherapy ICI+ICI ICI+TKI 4 (19)9 (43)8 (38) 46 (28)64 (40)51 (32) 0.64 Immunotherapy cycles (>4), n (%) 8 (50) 49 (37) 0.42 Median (IQR) clinical tumor size, cm 9.3 (6.7 – 11.9) 8.4 (6.6 – 12) 0.68 Clinical nodal involvement, n (%) 8 (38) 53 (33) 0.63 Clinical thrombus, n (%) 12 (57) 60 (37) 0.1 ICI: immune checkpoint inhibitor; TKI: tyrosine kinase inhibitor.
Multisociety multispecialty position statement on corticosteroid injections and influenza and COVID-19 vaccine administration
Benzon, Honorio T, FitzGerald, John, Flaherty, John P., Cohen, Steven Paul, Doshi, Tina L , Mina, Maged, Abd-Elsayed, Alaa, Eckmann, Maxim , Elmofty, Dalia , Hirsch, Joshua Adam, Hoang, Thanh Tuan , Manchikanti, Laxmaiah, Pino, Carlos, Rana, Maunak V., Rivera, Jessica , Shah, Shalini, Schneider, Byron J. , Souza, Dmitri , Stout, Alison, Maus, Tim, Cohen, Steven P. , Benzon, Honorio T. , FitzGerald, John , Benzon, Honorio T , Cohen, Steven P , Chadwick, Andrea , Hunt, Christine , Nagpal, Ameet S , Nelson, Ariana M , Pino, Carlos A , Provenzano, David Anthony , Shankar, Hariharan , Wasan, Ajay D , Narouze, Samer , Doshi, Tina L , FitzGerald, John D , FitzGerald, John, Abdi, Salahadin , Abd-Elsayed, Alaa A , Manchikanti, Laxmaiah , Nagpal, Ameet , Nelson, Ariana M. , Pino, Carlos A. , Provenzano, David , Rivera, Jessica, Shankar, Hariharan , Shanthanna, Harsha , Wasan, Ajay D. , Narouze, Samer , Maus, Timothy P.

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107556

10.1136/rapm-2025-107556 | PMID 41760373 Get It

Background Corticosteroid injections (CSIs) are widely employed for chronic pain. These injections include peripheral nerve blocks and trigger point injections, injections of large appendicular joints, the axial facet and sacroiliac joints, and the epidural space. These injections may be performed in patients who have been recently vaccinated or plan to be vaccinated. This multisociety multispecialty position statement aims to develop evidence-based statements and recommendations (SRs) on the safe interval between CSIs and COVID-19 and influenza vaccine administration. Methods Development of the position statement was approved by the American Society of Regional Anesthesia and Pain Medicine Board of Directors and several other societies that agreed to participate. The scope of the SRs was agreed on to include the efficacy of COVID-19 and influenza vaccines, adverse events related to the CSIs, specifically the effect of CSIs on the hypothalamic–pituitary axis, incidence of COVID-19 in patients who had CSIs during the pandemic, incidence of influenza in patients who had CSIs during the influenza season, and recommend a reasonable interval between CSIs and COVID-19 and influenza vaccination 20 mg/day of prednisone s. Experts were assigned topics to perform a comprehensive literature review and draft SRs, which were refined and voted for consensus (≥75% agreement) using a modified Delphi process. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. Results All SRs were approved by all participants after four rounds of discussion. The Practice Guidelines Committees and Boards of Directors of the participating societies also approved all SRs. If a vaccine has been recently administered or planned, then for non-urgent indications, the CSI should be offered at least 1 week before or after vaccine administration. For healthy patient(s), CSI, or vaccine administration may be performed without a 7-day interval after informed discussion with the patient and consent regarding the risk of blunted vaccine efficacy. For non-healthy patients, shared decision-making should include discussion of diminished vaccine effectiveness and the possibility of influenza or COVID-19 infection. Conclusions In this position statement, we provide recommendations on the optimal timing between CSIs and COVID-19 or influenza vaccine.
Optimizing Antimicrobial Stewardship in Hospital‐at‐Home Programs: On Behalf of the Society of Infectious Diseases Pharmacists
Pertzborn, Margaret , Peinovich, Margaret , Webster, Leah W., Cid, Allison , Ausman, Sara , Rivera, Christina G. , (SIDP), Society of Infectious Diseases Pharmacists, Webster, Leah C. Whitman , Webster, Leah Whitman , Rivera, Christina G , Ausman, Sara E

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | February 20, 2026 | Volume: 9 | Issue: 3 | Pages: No page available

10.1002/jac5.70185 | PMID 42009438 Get It

ABSTRACT Hospital‐at‐Home (HaH) programs provide acute care in patients' homes, reducing hospitalization and improving patient experience. While crucial in traditional settings, antimicrobial stewardship (AMS) in HaH programs remains understudied. This manuscript explores the potential benefits of AMS in HaH and the role of infectious diseases (ID) pharmacists in optimizing antimicrobial therapy. Key challenges in implementing AMS in HaH include medication delivery logistics, treatment regimen adjustments, and unique administration techniques. ID pharmacists can address these challenges by providing expertise in antimicrobial selection, dosing, and duration, as well as identifying opportunities for de‐escalation and intravenous (IV) to oral conversions. By integrating AMS into HaH programs, health care systems can improve patient outcomes, reduce antimicrobial resistance, and optimize resource utilization. Further research and training programs are needed to fully realize the potential of AMS in this emerging model of care.